To Compare the Efficacy and Safety of BP102 vs. Avastin® in Combination With Paclitaxel/Carboplatin in First-line Treatment of Advanced or Relapsed NSCLC

Exclusion Criteria

• •1. Patients with non-small cell lung cancer of other pathological tissue types;
• •2. Tumor histology or cytology confirmed positive ALK fusion gene;
• •3. Patients with imaging evidence of tumor invasion of large blood vessels;
• •4. Patients with uncontrolled pleural effusion and pericardial effusion that require repeated drainage;
• •5. Patients with abdominal effusion;
• •6. During the screening period, chest CT showed tumor cavity formation, or CT scan was highly suspected of idiopathic pulmonary fibrosis, mechanized pneumonia, drug-associated pneumonia, idiopathic pneumonia or active pneumonia;
• •7. Patients with hypertension whose blood pressure has not been satisfactorily controlled by antihypertensive drugs, and patients with previous hypertensive crisis or hypertensive encephalopathy;
• •8. Have heart disease or clinical symptoms that are not well controlled;
• •9. Patients with unhealed wounds, active gastric ulcers or fractures;
• •10. Patients diagnosed with esophagotracheal fistula;
• •11. People with known hereditary bleeding tendency or coagulation disorder;
• •12. Patients with known central nervous system metastases.